The role of coronavirus infection in the development of decompensation of cardiovascular diseases. Therapy options


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents current data on the impact of viral infection, including coronavirus SARS-CoV-2, on the development of decompensation of cardiovascular diseases. The use of cytochrome C is justified in patients with cardiovascular disease.

Full Text

Restricted Access

About the authors

I. B Zueva

Saint-Petersburg Medico-Social Institute

Email: iravit@yandex.ru
MD Saint-Petersburg

O. Yu Plaksin

OOO «Samson-Med»

Email: iravit@yandex.ru
Saint-Petersburg

References

  1. Li J.-Y., You Z., Wang Q. et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future // Microbes Infect. - 2020; 22 (2): 80-5. doi: 10.1016/j.micinf.2020.02.002.
  2. Guan W.J., Ni Z.Y., Zhong N.S. et al. Clinical characteristics of 2019 novel coronavirus infection in China // Med. Rxiv. - 2020; [Epub ahead of print]. https://doi.org/10.1101/2020.02.06.20020974.
  3. Yang Y., Lu Q.B., Liu M.J. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China // Med. Rxiv. - 2020; [Epub ahead of print]. https://doi.org/10.1101/2020.02.10.20021675.
  4. Liu Y., Gayle A.A., Wilder-Smith A. et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus // J. Travel Med. - 2020; [Epub ahead of print]. doi: 10.1093/jtm/taaa021.
  5. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. - 2020; 395: 497-506. DOI: 10.1016/ S0140-6736(20)30183-5.
  6. Du R.H., Liang L.R., Yang C.Q. et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study // Eur. Respir. J. - 2020; Apr 8. doi: 10.1183/13993003.00524-2020.
  7. Banerjee A., Kulcsar K., Misra V. et al. Bats and coronaviruses // Viruses. -2019; 11 (1): 41. doi: 10.3390/v11010041.
  8. Yang D., Leibowitz J.L. The structure and functions of coronavirus genomic 3 and 5 ends // Virus Res. - 2015; 206: 120-33. doi: 10.1016/j.virusres.2015.02.025.
  9. Villar J., Zhang H., Slutsky A.S. Lung repair and regeneration in ARDS: role of PECAM1 and Wnt signaling // Chest. - 2019; 155: 587-94. DOI: 10.1016/j. chest.2018. 10.022.
  10. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin. Immunopathol. - 2017; 39: 529-39. doi: 10.1007/s00281-017- 0629-x.
  11. Wan Y., Shang J., Graham R. et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decadelong structural studies of SARS // J. Virology. - 2020; 94 (7): pii: e00127-20. doi: 10.1128/JVI.00127-20.
  12. Li X.C., Zhang J., Zhuo J.L. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases // Pharmacol. Res. - 2017; 125: 21-38. doi: 10.1016/j.phrs.2017.06.005.
  13. Шляхто Е.В., Конради А.О., Арутюнов Г П. и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19 // Росс. кардиол. журн. - 2020; 25 (3): 3801 https://doi.org/10.15829/1560-4071-2020-3-3801
  14. Чеснокова Н.П., Понукалина Е.В., Бизенкова М.Н. Молекулярноклеточные механизмы цитотоксического действия гипоксии // Научное обозрение. Медицинские науки. - 2017; 2: 60-3
  15. Jessup M., Abraha W.T., Casey D.E. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation // Circulation. - 2009; 119 (14): 1977-2016. doi: 10.1161/CIRCULATIONAHA.109.192064.
  16. Hunt S.A., Abraham W.T. Chin M.H. et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society // Circulation. - 2005; 112 (12): e154-e235. doi: 10.1161/CIRCULATIONAHA.105.167586.
  17. Dong N., Cai J., Zhou Y. et al. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV // JACC: Heart Failure. - 2020; [Epub ahead of print]. https://doi.org/10.1016/jjchf.2020.04.001.
  18. Bayeva M., Gheorghiade M., Ardehali H. Mitochondria as a therapeutic target in heart failure // J. Am. Coll. Cardiol. - 2013; 61: 599-610. doi: 10.1016/j.jacc.2012.08.1021.
  19. Neely J.R., Liebermeister H., Battersby E.J. et al. Effect of pressure development on oxygen consumption by isolated rat heart // Am. J. Physiol. -1967; 212: 804-14.
  20. Gheorghiade M., Larson C.J., Shah S.J. et al. Developing new treatments for heart failure: focus on the heart // Circ. Heart Fail. - 2016; 9(5): pii: e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727.
  21. Boylston J.A., Sun J., Chen Y. et al. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury // J. Mol. Cell. Cardiol. -2015; 88: 73-81. doi: 10.1016/j.yjmcc.2015.09.005.
  22. Jenkins C.M., Yang K., Liu G. et al. Cytochromecis an oxidative stress-activated plasmalogenase that cleaves plasmenylcholine and plasmenylethanolamine at thesn-1 vinyl ether linkage // J. Biol. Chem. - 2018; 293 (22): 8693-709. doi: 10.1074/jbc.ra117.001629.
  23. Vaduganathan M., Butler J., Pitt B. et al. Contemporary drug development in heart failure: call for hemodynamically neutral therapies // Circ. Heart Fail. - 2015; 8: 826-31. doi: 10.1161/CIRCHEARTFAILURE.115.002271.
  24. Хансон К.П., Манойлов С.Е., Полосова П.Г. Влияние экзогенного цитохрома С на окислительное фосфорилирование в некоторых органах животных при экспериментальном опухолевом росте и лучевой болезни. Митохондрии / М.: Наука, 1967; с. 68-71
  25. Манойлов С.Е., Нестерова Л.А., Орлова И.А. и др. Действие цитохрома С, галактозы и уридинтрифосфата на рост перевиваемых опухолей // Вопр. онкол. - 1973; 19 (7): 62-5
  26. Слепнева Л.В., Ханевич М.Д., Зыбина Н.Н. и др. Цитохром С и его клиническое применение / Л.: ЛНИИГиПК, 1990; с. 27-31
  27. Мхитарян Л.М. Механизм лечебного действия цитохрома С при остром вирусном гепатите В // Экспериментальная и клиническая медицина. - 1987; 27 (6): 585-9
  28. Новиков В.С. Цитохром С и его клиническое применение / Л.: ЛНИИГиПК, 1990; с. 52-7
  29. Семенова И.Г., Баллюзек М.Ф., Тугушева Ф.А. Эффективность терапии больных хронической сердечной недостаточностью и нарушениями ритма сердца препаратом цитохром C // Фарматека. - 2013; 10: 51-6
  30. Яковлев Г.М., Ардашев В.Н. Применение препарата Цитохром С для превентивной терапии осложнений острого инфаркта миокарда // Ремедиум Приволжье. - 2009; 31-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies